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Abstract
Introduction—The ongoing surge of resistance of bacterial pathogens to antibiotic therapies and
the consistently aging median member of the human race signal an impending increase in the
incidence of chronic bone infection. Nanotechnological platforms for local and sustained delivery
of therapeutics hold the greatest potential for providing minimally invasive and maximally
regenerative therapies for this rare but persistent condition.
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Areas covered—Shortcomings of the clinically available treatment options, including
poly(methyl methacrylate) beads and calcium sulfate cements, are discussed and their
transcending using calcium-phosphate/polymeric nanoparticulate composites is foreseen. Bone is
a composite wherein the weakness of each component alone is compensated for by the strength of
its complement and an ideal bone substitute should be fundamentally the same.
Expert opinion—Discrepancy between in vitro and in vivo bioactivity assessments is
highlighted, alongside the inherent imperfectness of the former. Challenges entailing the crossdisciplinary nature of engineering a new generation of drug delivery vehicles are delineated and it
is concluded that the future for the nanoparticulate therapeutic carriers belongs to multifunctional,
synergistic and theranostic composites capable of simultaneously targeting, monitoring and
treating internal organismic disturbances in a smart, feedback fashion and in direct response to the
demands of the local environment.
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1. Introduction
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Since the advent of the antibiotic era, infectious diseases have lost a place at the forefront of
interest of biomedical research in the developed world. For many decades now, with the
exception of HIV, the concern for contracting a major infection among individuals with
uncompromised immune responses has been confined to the Third World countries. Not
only does the overall National Institutes of Health funding for infectious diseases and their
clinical corollaries currently comprise mere 10% of its overall amount, but the funding for
rural health in 2014 has, for example, outstripped that for malaria by > 50% [1]. However,
with the evolution of bacterial resistance to the current generation of antibiotics and the
corresponding proneness to latent viral outbreaks, this state of affairs is expected to change
in the near future. Finding the treatment for the hyperaggressive forms of bacterial infections
before the humanity witnesses an impending pandemic of devastating proportions proves as
necessary and might, moreover, require a fundamentally different therapeutic approach
compared to the one that has been embraced in the past.
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Bone is an organ shielded well from the external pathogens, which is a double-edged sword
from the clinical standpoint. For, to the same extent that it resists infection, it resists
therapies against the occurring infections. Despite the extensive research, osteomyelitis
proves difficult to treat and its chronic forms usually entail poor prognosis for the patient
[2]. The difficulty of its treatment is further increased due to the fact that a wide variety of
pathogens can cause it, including fungus, pox viruses as well as not so common bacteria,
such as Haemophilus influenzae, Brucella suis, Mycobacterium tuberculosis,
Mycobacterium ulcerans, Fusobacterium nucleatum and others, aside from the pyogenic
bacteria from the healthy oral flora, which remain its main causative agents. Staphylococcus
aureus and Staphylococcus epidermis are held responsible for the great majority of bone
infections, ~ 90%, whereby the increasing incidence of their methicillin-resistant forms
explains the unusual severity of the recent clinical manifestations of this disease
characterized by a high recurrence rate despite the extensive surgical interventions and longterm antibiotic therapies [3].

Author Manuscript

Historically, given that osteomyelitis is one of the oldest documented diseases, whose first
reports date back to Hippo-crates’ scripts from the 5th century BC [4] and whose oldest
known evidence lies in the fossilized spine of a 270 million-year-old Permian reptile [5],
significant advances in its treatment have been made in the past [6]. Before the introduction
of penicillin in the 1940s, chronic osteomyelitis was treated first by amputation, then by
trepanning and less-invasive surgeries [7] with or without the application of various natural
medicines, including such ointments as bovine feces or larva of the blow fly [8]. Mainstay of
therapy for the last 50 years has, however, been a concoction of oral and parenteral
antibiotic therapy, lasting up to 2 –12 weeks, depending on the severity of the infection, and
surgical debridement of necrotic bone. The room for the improvement of this traditional, yet
rather deficient, approach to the treatment of osteomyelitis is, however, obvious to those
familiar with the sophisticated drug delivery technologies currently existing in the
embryonic or translational stages (Figure 1). Its elaboration from a bionanotechnological
perspective presents the subject of this opinion piece.
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2. Shortcomings of the traditional therapies and the available local release
alternatives
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Two of the major downsides of the traditional therapy for osteomyelitis are fairly obvious.
First, the surgical removal of diseased bone entails weakening of the musculoskeletal
support and causes unaesthetic disfigurements, frequently demanding the implantation of
permanent braces besides bone grafting. Second, antibiotics administered systemically have
a hard time crossing the sequestra (and the relatively avascular sclerotic bone surrounding it)
and reaching the infection site, which does not only diminish their effectiveness, but also
increases the chances for the induction of resistance of the pathogen to the actual antibiotic
therapy. Logically, these two central shortcomings could be ameliorated with the use of
platforms capable of locally and sustainably delivering antimicrobial agents while
stimulating tissue regeneration and substitution of necrotic foci with the newly formed,
healthy bone.

Author Manuscript
Author Manuscript

At the clinical level, these innovative strategies remain only partially implemented and that
mainly in the form of poly (methyl methacrylate) (PMMA) beads. After they had been first
clinically applied in the early 1970s [9], they gradually established themselves as a standard
option for the local delivery of antibiotics to bone cavities and this trend continues to this
very day. Although PMMA beads loaded with hydrophilic antibiotics were successfully
applied in the past [10–12], numerous clinical limitations are associated with their use.
These include: i) their nonbiodegradable nature and the need for a secondary surgical
procedure to ensure their removal from the body after the release process is over [13]; ii) an
often insubstantial amount of the released antibiotic following the initial, burst release phase
[14], which has led to the promotion of pathogenic resistance to such therapies in the past
[15]; iii) proneness to biofilm formation, which hinders the antimicrobial action [16]; and iv)
moderate toxicity resulting from the absorption of MMA monomers and the
carboxylesterase-mediated conversion of MMA to methacrylic acid [17]. On top of this, a
comprehensive clinical study has yet to prove that PMMA beads are more effective than the
systemic antibiotic delivery in treating orthopedic infections [18]. The major clinically
available alternative capable of sustained release are calcium sulfate cements, which suffer
from other weaknesses, mainly their rapid degradation time scale, in the order of weeks,
which is faster than the bone ingrowth rate and can lead to the mechanical implant failure
[19], alongside other clinical issues, such as drainage at the wound site [20], severe
inflammation secondary to overabundance of calcium ions [21], and the occurrence of
fibrous gaps in the zones undergoing the replacement of the rapidly resorbing cement with
the slowly growing bone [22]. However, with the current knowledge of sophisticated drug
delivery vehicles, devising a new generation of locally targeted and minimally invasive
therapies for osteomyelitis could be readily foreseen.

3. Biodegradable poly(α-hydroxy esters): pros outweighed by cons
Biodegradable polymeric carriers, for example, pose themselves as a natural alternative to
the use of PMMA. To this end, the favorite choice has fallen on poly(α-hydroxy esters),
including poly(L-lactic acid) (PLLA), poly(glycolide) (PGA) and poly-(D,L-lactide-coglycolide) (PLGA), all of which have been experimentally applied as antibiotic carriers for
Expert Opin Drug Deliv. Author manuscript; available in PMC 2015 April 12.
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the treatment of osteomyelitis [23–25]. An immediate upside of their application comes
from their ability to encapsulate comparatively large amounts of both hydrophobic and
hydrophilic drugs [26] and exhibit extended drug release profiles [27]. The latter can be
furthermore made tunable via control over composition and processing conditions [28]. In
the case of PLGA, for example, the lactide-to-co-glycolide ratio could be used as a control
parameter in setting the degradation and release time scales under physiological conditions
to range from a year or more for PLLA to around 6 months for PLGA with the lactide-to-coglycolide ratio of 1:1 to about a month for pure PGA. A detrimental effect that entails the
use of poly (α-hydroxy esters) and that was observed in the past is that their acidic
degradation products may favor the bacterial growth and promote hard tissue resorption and
bone mass loss [29,30]. Chronic inflammation is, in fact, known to often result as a response
to implantation of PLLA-based polymers in bone tissue engineering [31–33]. Since the
antimicrobial effectiveness of antibiotics is found only within a relatively narrow window of
pH values and could decrease by as much as 16-fold following a pH drop from 7.4 to 5.5
[34], this acidification entailing partial or complete degradation of poly (α-hydroxy esters)
can negatively interfere with the antimicrobial action. Despite their superior release
properties, this has suggested the necessity of combining poly(α-hydroxy esters) with
alkaline inorganics, such as calcium phosphates [35].

4. Calcium phosphates
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Calcium phosphates have been traditionally considered as a favorite choice for the synthetic
substitute of hard tissues due to their structural and compositional versatility, outstanding
biocompatibility and bioactivity, and the ability of being conducive to new bone growth.
The major weakness of this material springs from the fact that it resists encapsulation of
drugs via intercalation. Calcium phosphates are, on the other hand, excellent adsorbents of
an array of organics, the reason for which their least-soluble phase, hydroxyapatite, has been
used as a chromatographic adsorbent of proteins and nucleic acids [36,37]. This property of
theirs, however, comes at a cost because it predisposes them in turn to exhibit burst release
and puts definite limits on their capacity to release substantial amounts of drugs over
prolonged periods of time. Although some level of burst release is desired to some extent in
the treatment of infectious diseases, lest the targeted bacterial populations become
potentially resistant to the administered antibiotic, the release from calcium phosphates is
typically such that 80 –90% of the drug becomes desorbed in the first minutes of contact
with the physiological solution or body fluids [38]. The simplest way to overcome this issue
has involved intraporous loading of nanoparticulate aggregates with a drug either using high
pressure [39,40] or spontaneous powder compaction and drug capture upon desiccation [41].
These strategies, however, interfere with the attempts to produce injectable colloidal calcium
phosphate gels and question the veracity of their nanoparticulate nature if they come to be
applicable as solely implantable microscopic aggregates of nanoparticles.
Calcium phosphates belong to structurally complex ceramics wherein the stoichiometric
composition could be used to tailor the properties of interest. Figure 2A illustrates the use of
another ceramic compound, lanthanum-strontium manganite, in producing tunable and selfregulating superparamagnetic materials for the treatment of cancer via hyperthermia.
Namely, by varying the ratio between lanthanum and strontium, that is, parameter x in
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nanosized La1-xSrxMnO3 + δ, the Neel point of the material changes in the range of T = 25 –
100°C for x = 0.16 –0.5, enabling the use of the material for hyperthermic, thermoblastic or
even more intense thermal tissue healing applications [42]. Similarly, calcium phosphates
can be synthesized in a variety of stoichiometries, covering the range of solubility values
from 18 g/dm3 for anhydrous and monohydrous monocalcium phosphates (triclinic
Ca(H2PO4)2) to 88 mg/dm3 for brushite (monoclinic CaHPO4·2H2O) to 48 mg/dm3 for
monetite (triclinic CaHPO4) to 17 mg/dm3 for calcium pyrophosphate (tetragonal Ca2P2O7)
to 2.5 mg/dm3 for α-tricalcium phosphate (monoclinic Ca3(PO4)2) to ~ 1 mg/dm3 for
amorphous calcium phosphate to 0.3 mg/dm3 for hydroxy-apatite (pseudo-hexagonal
Ca10(PO4)6(OH)2). In such a manner, the composition could be a control parameter for the
solubility, that is, the degradation rate, which could be, in turn, used as a control parameter
for the drug release. Figure 2B correspondingly demonstrates the use of different calcium
phosphate phases for achieving different rates of release of bovine serum albumin [43].
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Another ceramic material offering similar tailoring of the degradation rate to a desired
kinetic profile via control of its stoichiometry is bioactive glass, which has also been
researched extensively as a carrier for the sustained release of antibiotics in the treatment of
orthopedic infections [44]. Such adjustments of the degradation rate could be achieved, for
example, by controlling silicate-to-borate ratio [45] or the amount of a less-abundant
constitutive ion, such as sodium [46] or strontium [47]. Still, given the fact that silicon, the
main cationic component of all types of bioactive glasses, is but a trace element in the
human body, present in the amount of only 1 –2 g [48], as well as that their amorphous
network of silica tetrahedra partially, yet usually incompletely [49], transforms to
hydroxyapatite in the body raises fundamental issues regarding their usability as bone
substitutes, especially when compared with a more natural compound of choice: calcium
phosphate.
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Being the sole component of the mineral phase of hard tissues, calcium phosphates are
natural candidates for bone-filling drug carriers. With bone acting as a natural reservoir for
calcium and phosphate ions [50], any excessive amounts thereof could be regulated in favor
of new bone growth. Calcium and phosphate ions released upon degradation stimulate
osteoblastic differentiation [51,52] and proliferation [53] and could be used as ionic
ingredients for the new bone formation. Another advantage of calcium phosphates is that
they could be readily made into self-setting pastes, injectable upon mixing, yet setting into
firm solids after the injection [54]. Unlike polymers, calcium phosphates tolerate well the
exposition to γ-irradiation, gas plasma discharge and supercritical CO2 and could be
sterilized using any of those without any concerns that their structural properties would be
damaged thereby. Calcium phosphate particles could be also fabricated in a variety of
morphologies and nanosize presents their natural, most easily obtainable state by
precipitation from aqueous solutions [55].

5. The biomimetic argument
Biomimetics, it is worth noticing, is one of the most prospective principles that guide tissue
engineers in designing a new generation of biomaterials [56,57]. In this case, it can be
summed as similia similibus curantur, necessitating the substitution of like with like. First,
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because bone is an organic/inorganic composite, it could be argued that a composite of a
similar nature is to be used as its ideal substitute. Second, bone is a nanostructured
composite, given that at the molecular level it comprises ~ 30 × 20 × 2 nm-sized calcium
phosphate crystals interspersed within the collagen matrix [58]. Third, we have seen that
calcium phosphate as the key inorganic ingredient of bone suggests the ideality of its usage
as a core nanostructured component of composites for bone regeneration. Finally, bone is a
multifunctional biological material involved in biomechanical support and protection of the
body, production of blood cells and mineral ion storage. Therefore, it is natural to expect
that the ideal material for its replacement should also be multifunctional. This is where we
arrive once again at the simultaneously antimicrobial and regenerative role for the new
generation of drug delivery platforms for the prophylactic and/or restorative treatments of
bone affected by osteomyelitis. This idea is logical in view of the dual purpose that an ideal
therapeutic agent is to serve in general: i) to eradicate the internal manifestation of illness;
and ii) to revitalize the organism.
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Biological techniques applicable in the assessment of the regenerative capacities of these
platforms can be divided to morphological, genetic, proteomic and metabolic ones and are
illustrated in Figure 3. Immunohistochemistry presents a valuable tool in understanding the
osteoconductivity of materials by measuring the affinity of the cell to the surface of the
carrier, as shown in Figure 3A. Expression of osteogenic markers at the mRNA level,
including, most notably and least ambiguously, osteocalcin, Runx2 and osterix, could give
an insight into the bone-building activity of osteoblasts in contact with the material (Figure
3B). The expression of proteins implicated in bone mineralization can be quantified to
conclude about the osteogenic potency of the material (Figure 3C), while smaller cytokines
and metabolites involved in signaling between osteoblasts and osteoclasts, the two types of
cells that in a mutually antagonistic manner orchestrate the bone regeneration process, could
be equally reliable indicators of the osteogenic response of the cells to a given material.
Such molecules include members of the osteoprotegerin/receptor for activation of NF-kB
ligand (RANKL)/RANK pathway, where RANKL is a tumor necrosis factor family member
secreted by osteoblasts with a role to trigger the differentiation of mesenchymal stromal
cells to osteoclasts and speed up the complementary bone degradation processes. Finally, the
measurements of calcitriol, the active form of vitamin D, or retinoic acid (RA), both of
which are crucial for the proper skeletal development, could be indicative of the osteogenic
process, owing to the fact that their concentration increase corresponds to the upregulation
of protein species in the osteogenic pathway, directly in the case of calcitriol [59] and
inversely in the case of RA [60,61]. Figure 3D and E shows chromatograms of vitamin D
metabolites extracted from a human sample using an antibody binding specifically to 1,25dihydroxycholecalciferol [62] and a direct proportionality between its concentration at the
cellular level and the osteogenic activity of the cells [63].

6. Targeting the intracellular colonies
The antibiotic treatments of osteomyelitis are greatly hampered due to the ability of S.
aureus, its main causative agent, to penetrate osteoblastic and other cells and form a
temporary symbiosis with them [64,65], before inducing their apoptosis and continuing to
spread across the organism [66]. Though far more difficult to achieve, targeting these
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intracellular colonies by the antibiotic therapy is thus expected to be more important for
preventing the recurrence of infection than eradicating only the pathogens that colonize the
bone matrix [67]. Calcium phosphate nanoparticles are the major nonviral agents for the
intracellular delivery of plasmids [68,69], which explains the fact that, loaded with
clindamycin phosphate, they diminished the presence of S. aureus colonies located within
osteoblastic cells in vitro to a greater degree than it was achieved by the application of the
pure antibiotic [70]. Figure 4A shows a schematic description of the nanoparticle uptake by
the cell, while Figure 4B demonstrates the intracellular localization of calcium phosphate
nanoparticles observed during an immunofluorescent analysis of their interface with
osteoblastic cells.

7. The prospect of composites
Author Manuscript
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The aforementioned arguments speak in favor of composite nanoparticles as the most
prospective ones in ensuring simultaneously therapeutic and regenerative performance.
Although increased bioactivity usually comes at the cost of increased proneness to biofilm
formation, an optimal balance between the antibacterial (therapeutic) and the osteogenic
(regenerative) performance of biomaterials designed to cope with bone infection must be
found. And the fact that multiple functionalities are to be achieved by these materials points
in the direction of composites as the forthcoming generation of materials for bone
engineering. In addition, bone itself is a composite wherein the weakness of each component
alone is compensated for by the strength of its complement and it could be argued that an
ideal bone substitute should be fundamentally similar in nature. Polymeric coatings are
capable of stabilizing the drug adsorbed on the surface of calcium phosphate nanoparticles
and serving as an additional reservoir for drug encapsulation and its more sustained release
[71], alongside offering a more stable surface for conjugation with targeting, optically active
or other therapeutic ligands [72]. An alternative concept employs a nanoparticulate,
microporous calcium phosphate shell formed around the polymeric core [73]. This reverse
method aims to harness the osteoconductive nature of the ceramic phase to a greater extent,
while still enabling the drug to be released sustainably from the core polymeric reservoir
through the surface pores.
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From the mechanical standpoint, it is generally assumed that the microstructure of calcium
phosphates alone cannot be modified in such a manner as to make the material mechanically
compatible with the grafted bone and eliminate the risk of filler fracture after its surgical
placement [74]. Only in combination with a soft component could calcium phosphates
overcome these fundamental problems associated with their clinical application. For
example, the combination of visco-elastic polymers and osteoconductive calcium
phosphates has yielded composites that surpassed the resistance to fracture, the structural
integrity and the stiffness of individual components [75], making up for the low compressive
strength of the former and brittleness and the lack of malleability of the latter [76]. Finally,
the resorption time and the corresponding bone ingrowth rate significantly increased when
hydroxyapatite was implanted as a bone substitute in vivo in a composite form, in
combination with PLGA [77,78], a polymer known to be able to accelerate the resorption of
calcium phosphates by the release of its acidic degradation products [79].
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Of course, sky is the limit when it comes to conceiving additional components of such basic
soft/hard organic/inorganic matrices that crudely mimic bone. Combinations of calcium
phosphate, PLGA and semiconductor quantum dots at the nanoparticle scale have, for
instance, enabled monitoring of the particle routes in the body [80,81]. Many of the readily
imaginable options are, however, yet to be explored. Conjugation of the carrier particles to
moieties that have an affinity for various bone components [82], such as bisphosphonates
[83] or estrogen [84], acting as either targeting agents or metabologens, is one and the
enrichment of antibiotic carriers with pluripotent cells, such as mesenchymal stem cells able
to differentiate into osteoblasts [85], is another. Supplementation of particles with elements
or surfaces with pronounced antimicrobial activities as alternatives to traditional antibiotics,
always prone to induce the globally spreading resistance of pathogens to them, presents
another prosperous direction of research. Shown in Figure 5 is an example of monodisperse,
composite and antibiotic-free nanoparticles with simultaneously antioxidative, antibacterial
and osteoinductive properties. The particles were able to: i) reduce the concentration of
superoxide in human umbilical vein endothelial cells; ii) suppress the growth of E. coli and
methicillin-resistant S. aureus; and iii) upregulate the expression of two osteogenic markers:
osteocalcin and protocollagen type I.

8. Expert opinion
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So far we have described the discrepancy between the therapeutic state of the art in coping
with the cases of osteomyelitis in the clinic and the existing drug delivery technologies. In
broader terms, a new set of regulations may be needed to facilitate the translational path
between the bench and the clinic, lest this gap continues to widen. Also, enabling a greater
flux of ideas from materials science centers of thought to the world of biology and medicine
will be of benefit for the process of discovery of advanced nanoscale drug delivery
platforms. One way to achieve this is to stimulate the opening of materials science centers in
the core of medical school environments and convert physical proximity to fruitful
collaboration around specific clinical priorities. Engineering a new generation of drug
delivery vehicles is, after all, a discipline at a crossroads, requiring an input from the
materials scientists, physical chemists, mechanical engineers, pharmacologists, molecular
and cell biologists and, crucially, clinicians. How to balance the congregation of such a
multitude of outlooks that often sound foreign to each other with maintaining an in-depth
perspective toward a given therapeutic goal is a challenge for the new generation of
principal investigators. In the end, with the subjects of research reflecting their qualities
back to researchers, it comes as natural that a new generation of materials will raise a new
generation of materials scientists developing them.
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More specifically, an ideal material for bone infection therapies would be an injectable
colloid capable of adhering to the defected bone mass, possibly through a self-setting
mechanism. It would then proceed to release the antimicrobial pay-load to the areas of
infection in a sustained and targeted manner, thwarting its progress while also being able to
foster the resorption of the necrotic bone and its replacement with the newly grown one. The
abovementioned similia similibus curantur maxim has guided us in the direction of calcium
phosphates as ideal core components of complex composite materials that are to be
developed for this application. Biological techniques have been set in place to facilitate the
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assaying of favorability of the cell response to the given materials in vitro, prior to their use
in animal or clinical studies, yet a lot of work to conquer significant challenges lies ahead.
For example, the rapid reorganization of the surface layers of ionic compounds in aqueous
media disables their functionalization with therapeutic ligands that would be of a
comparable level of stability as that achievable using silanol, thiol and phos-phonic acid
moieties on the surfaces of silica, gold and quantum dot nanoparticles, respectively. To
overcome this issue, however, exciting composites with versatile surface compositions,
structures and functional synergies have been created, proving that problems are indeed the
mothers of invention.
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An essential issue that needs to be mentioned pertains to the fundamental unreliability of in
vitro studies per se. For example, the same vitamin D derivative produced thoroughly
different effects on differentiation and mineralization in two different osteoblast-like
cultures: catabolic in one and anabolic in another [86]. Or, whereas mild cytotoxicity can
wipe out cells cultured in dishes, it can provide conditions for an optimal inflammatory
response that stimulates a cascade of regenerative processes in tissues [87–89]. Then, as
elaborated earlier [90], drug release profiles observed in vitro and often mistakenly used as
data to accompany in vivo observations are subject to change depending on the release
conditions (ionic strength and pH of the medium, its volume, temperature, replenishment
frequency, etc.), while any attempts to standardize their measurements would be
meaningless in view of the fact that any two given points in the body will have different
release environments. Next, there is a question of the commonly observed discrepancy
between the performance of a drug delivery technology in vitro and in vivo. A higher
concentration of enzymes, free radicals, antibodies and other protein species adsorbed on the
surface of the carriers could all significantly accelerate its degradation and increase the
kinetic order of the release profiles. These factors, in addition to phagocytosis and increased
wetting, are responsible for the fact that PLGA scaffolds, for instance, degrade faster in vivo
than in vitro [91]. We know now that although size, shape, surface charge, chemistry and
mechanical properties of nanoparticles influence their biodistribution profiles, the route of
uptake and the mechanism of interaction with the cell are mainly determined by their protein
corona [92], and similar effects are to be expected with respect to the cell and tissue
response to any material in a biological milieu. And whether the degradation and release will
be hindered or augmented greatly depends not only on the environment, but on the type of
the material too: thus, while the degradation of aliphatic polyesters is slowed down under
intense fluid flows due to dissipation of acidic byproducts that would have sped up the
degradation process, the fluid flow prevents local supersaturation/reprecipitation and
accelerates the degradation of alkaline calcium phosphates. On the other hand, although in
vivo analyses may yield more relevant insights as to how large or low the applicative
potential of given therapeutic platforms at the clinical level would be, the failure of drug
delivery devices and other implants for non-load-bearing applications begins from the tissue/
device interface and in vitro studies present expedient models for probing this interaction at
the basic levels, including cellular, biomolecular and quantum chemistry ones. Still, how to
devise in vitro drug release testing procedures that would be able to replicate in vivo
conditions better, typically characterized by: i) a more dynamic flow of fluids; ii) specific
local pH profiles that are often disease-dependent; and iii) much more complex and selective
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media, currently stands forth as a grand challenge before the drug delivery field. Complex
bioreactors for mimicking biological processes in need of better understanding [93] or
stimulating differentiation and assembly of stem cells [94] have been designed under the
conditions of continuous flow and using the same approach to create microenvironments for
more biologically relevant testing of release properties in vitro proves as a necessity from
the perspective of ensuring smoother transitions from the proof-of-concept stage to
commercial and clinically applicable drug delivery vehicles.
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There are, of course, many other systemic challenges that define the future of the field. For
example, as reports on synergetic effects between the components of drug delivery vehicles
multiply [95,96], it is time to reconsider the separation of drug discoverers from drug
deliverers, who have traditionally worked in virtual isolation from each other. With the
requirements to think fast and find reliable alternatives to antibiotics, which currently have a
hard time navigating between Scylla of the long regulatory path and Charybdis of the rising
microbial resistance, the need for the intercrossing of knowledge of materials scientists, drug
delivery experts and pharmacologists can hardly be overstated. In the end, with the rising
demands for therapeutic, regenerative and controlled delivery aspects of medical devices to
be crafted in synchrony, such broadening of views and tying specific experimental
approaches within ample multidisciplinary networks could be seen as all but evitable.
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This is all to say that the search for a perfect drug delivery carrier for the treatment of bone
dysfunction continues. Meanwhile, the room for design appears limitless and the future for
the field of nanoparticulate drug delivery carriers is certain in one sense only: it belongs to
multifunctional, synergistic and theranostic composite carriers capable of simultaneously
targeting, monitoring and treating internal organismic disturbances in a smart, feedback
fashion and in direct response to the demands of the local microenvironment and beyond.
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•

A great demand exists for the development of antimicrobial bone grafts.

•

Similia similibus curantur principle dictates that calcium phosphate should be
the key inorganic ingredient of composites for bone regeneration.

•

Biodegradable poly(α-hydroxy esters) are common compounds of choice for the
organic ingredient of composites for bone regeneration, but their shortcomings
are many and are discussed herein.

•

Staphylococcus aureus, the main causative agent of osteomyelitis, is able to
penetrate bone cells and form intracellular colonies, so that design of antibiotic
therapies that target them may be more relevant for treating chronic bone
infection than eliminating only the pathogens colonizing the bone matrix.

•

The problem of disparity between in vitro drug release testing procedures and in
vivo conditions that they mimic is discussed.

•

It is concluded that ideal implants or injects for orthopedic infection therapies
would be multifunctional composites capable of simultaneously targeting and
treating the disease from two angles: antimicrobial and osteogenic.

This box summarizes key points contained in the article.
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Figure 1. There is an increasing demand for contemporary drug delivery platforms to be
multifunctional, that is, to simultaneously: i) deliver the drug smartly, at the optimal rate and
amount over prolonged periods of time and in feedback with the characteristics of the local
microenvironment; ii) preserve the drug’s bioactivity in the biological milieu; iii) contribute to
tissue regeneration; iv) promote targeting of the right location at the cellular or subcellular level;
and v) act as traceable sensors to serve a diagnostic purpose in real time

Some of the sophisticated material structures intensely researched for such applications
include soft, hard and composite nano- and microparticles, thin films and surface coatings,
organic meshes, micelles and vesicles, and microfabricated patterns.
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Figure 2.
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(A) The derivative of specific magnetization over time as a function of temperature for
powders comprising nanosized La1-xSrxMnO3 + δ particles with different values of
parameter x [x = 0.16 (□), 0.24 (○), 0.33 (△) and 0.5 (▼)], with the local minima
corresponding to the Neel point of the material, the temperature at which the magnetic
moments become randomized due to thermal fluctuations. (B) Different kinetic profiles for
the release of albumin (FITC-BSA) from compacted nanostructured calcium phosphate
powders of different phase compositions: MCPM, DCPA, ACP and HAP.
Reprinted with permission from [42,43].
ACP: Amorphous calcium phosphate; DCPA: Dicalcium phosphate anhydrous; HAP:
Hydroxyapatite; MCPM: Monocalcium phosphate monohydrate.
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Figure 3.
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Morphological (A), genetic (B), proteomic (C) and metabolic (D) assessment of the
osteogenic effectiveness of nanoparticles delivering a therapeutic payload. (A)
Immunofluorescently counterstained osteoblasts (nuclei – blue; f-actin –red) are shown
adhering onto a microscopic conglomerate of calcium phosphate nanoparticles (green)
capable of delivering an antibiotic payload to the segments of infected bone; (B) mRNA
expression of three different osteogenic markers – osteocalcin (BGLAP), protocollagen type
I (Col I) and the transcription factor Runx2 – in osteoblasts seeded in the presence of
hydroxyapatite/PLGA core-shell composite particles is greater than in osteoblasts seeded in
the presence of pure hydroxyapatite, which is itself greater than in control osteoblasts; (C)
Western blot analysis of the expression of different proteins of the osteogenic pathway in the
presence of mineralized (M-PCL) and regular (PCL) poly(ε-caprolactone) at different time
points; (D) High-performance liquid chromatograms showing peaks of cholecalciferol
metabolites capable of increasing the concentration of osteocalcin secreted by osteoblasts
(E).
Reprinted with permissions from [71] and [97].
PLGA: Poly-(D,L-lactide-co-glycolide).
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Figure 4.

(A) A schematic description of the major pathways for the intracellular uptake of
nanoparticles. (B) A single-plane confocal optical image showing the localization of
aggregates of clindamycin-containing calcium phosphate nanoparticles (green) inside an
osteoblastic cell (nucleus – blue; cytoskeletal f-actin – red).
Reprinted with permission from [98].
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Figure 5. Composite monodisperse nanoparticles with simultaneous antioxidative, antibacterial
and osteoinductive properties made by coating PLGA around silver-PGA core-shell Np and
dispersing ascorbic acid inside them
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Adapted and reprinted with permission from [99,100].
Np: Nanoparticles; PGA: Poly(glycolide); PLGA: Poly-(D,L-lactide-co-glycolide).
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